![]() |
市場調査レポート
商品コード
1497623
CRISPR遺伝子編集市場:オファリング、技術、用途、最終用途別-世界予測2024-2030年CRISPR Gene Editing Market by Offering (Reagents & Consumables, Services, Software & Systems), Technology (Anti-CRISPR Proteins, CRISPR/Cas13, CRISPR/Cas9), Application, End-use - Global Forecast 2024-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
CRISPR遺伝子編集市場:オファリング、技術、用途、最終用途別-世界予測2024-2030年 |
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 191 Pages
納期: 即日から翌営業日
|
CRISPR遺伝子編集市場規模は2023年に32億5,000万米ドルと推計され、2024年には37億7,000万米ドルに達し、CAGR 16.81%で2030年には96億6,000万米ドルに達すると予測されています。
CRISPR-Cas9と呼ばれるCRISPR遺伝子編集は、遺伝学者や医学研究者がDNA配列の一部を追加、削除、変更することによってゲノムの一部を編集、変更することを可能にする画期的な生化学技術です。この技術は、最もシンプルで汎用性が高く、正確な遺伝子操作法のひとつです。遺伝子疾患の有病率の上昇と個別化医療に対する需要の高まりが、市場成長の要因となっています。さらに、バイオテクノロジーおよび製薬部門による研究開発への多額の投資、遺伝子編集アプリケーションに対する政府および規制当局の支援が、市場開拓を促進する上で重要な役割を果たしています。しかし、オフターゲット効果、ヒト生殖系列編集をめぐる倫理的懸念、環境における意図しない結果の可能性は、市場の成長を制限する重大な問題です。さらに、作物設計による精密農業の進展や、細胞および遺伝子研究手法の強化は、市場成長の有利な機会を生み出しています。
主な市場の統計 | |
---|---|
基準年[2023] | 32億5,000万米ドル |
推定年[2024] | 37億7,000万米ドル |
予測年 [2030] | 96億6,000万米ドル |
CAGR(%) | 16.81% |
地域別の洞察
南北アメリカ、特に米国とカナダでは、遺伝性疾患と慢性疾患の有病率が高いため、CRISPR技術の進歩に大きな重点が置かれています。消費者のニーズは個別化医療とCRISPRによる新規治療の可能性に集中しています。米国はCRISPR特許の最前線にあり、バイオテクノロジー大手や権威ある学術機関が注目すべき調査を行っています。欧州連合(EU)諸国は、バイオテクノロジーの応用を指導する強固な規制の枠組みを持っており、消費者のニーズと購買行動の両方に影響を与えています。厳しい規制の存在は、一方で徹底的で安全な開発を促すが、他方では技術革新と採用を遅らせる可能性があります。中東・アフリカ地域では、CRISPR技術はまだ導入の初期段階にあります。経済発展やヘルスケア・インフラのレベルが異なるため、消費者のニーズや顧客行動はこれらの地域によって大きく異なります。アジア太平洋地域は、CRISPR遺伝子編集にとって多様で急速に発展している市場です。中国では、CRISPR技術が国や民間から大規模な投資を受けており、特に医療と農業において実質的な研究と応用を推進しています。日本はこの分野への強力な投資を行っており、その技術的進歩と、遺伝子組換えに対する社会的懸念に配慮した規制との整合性を図っています。
FPNVポジショニング・マトリックス
FPNVポジショニングマトリックスは、CRISPR遺伝子編集市場におけるベンダーの市場ポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront(F)、Pathfinder(P)、Niche(N)、Vital(V)に分類されます。
市場シェア分析
市場シェア分析は、CRISPR遺伝子編集市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。
戦略分析と推奨
戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、CRISPR遺伝子編集市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。
[191 Pages Report] The CRISPR Gene Editing Market size was estimated at USD 3.25 billion in 2023 and expected to reach USD 3.77 billion in 2024, at a CAGR 16.81% to reach USD 9.66 billion by 2030.
CRISPR gene editing, referred to as CRISPR-Cas9, is a revolutionary biochemical technology that enables geneticists and medical researchers to edit and modify parts of the genome by adding, removing, and altering parts of the DNA sequence. It is one of the simplest, most versatile, and precise methods of genetic manipulation. The rising prevalence of genetic disorders, along with the increasing demand for personalized medicine, is owing to the market growth. Additionally, significant investments in research and development by biotech and pharma sectors and governmental and regulatory support for gene editing applications play a vital role in fostering market development. However, off-target effects, ethical concerns surrounding human germline editing, and the potential for unintended consequences in the environment are significant issues limiting the market growth. Furthermore, the advancement of precision agriculture through crop design and the enhancement of cellular and genetic research methods create lucrative opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 3.25 billion |
Estimated Year [2024] | USD 3.77 billion |
Forecast Year [2030] | USD 9.66 billion |
CAGR (%) | 16.81% |
Regional Insights
In the Americas, particularly the United States and Canada, there is a significant emphasis on the advancement of CRISPR technology due to the high prevalence of genetic disorders and chronic diseases. Consumer needs are focused on personalized medicine and the potential of CRISPR to provide novel treatments. The United States is at the forefront in terms of CRISPR patents, with notable research being conducted by biotech giants and prestigious academic institutions. European Union (EU) countries have a robust regulatory framework guiding biotechnology applications that impact both consumer needs and purchasing behavior. The presence of stringent regulations, encouraging thorough, safe development on the one hand but potentially slowing innovation and adoption on the other. In the Middle East and Africa regions, CRISPR technology is still in the nascent stages of adoption. Due to varying levels of economic development and healthcare infrastructure, consumer needs and customer behavior differ significantly across these territories. The Asia Pacific region presents a diverse and rapidly evolving market for CRISPR gene editing. In China, CRISPR technology is receiving massive state and private investment, pushing forward substantial research and applications, especially in medicine and agriculture. Japan demonstrates a strong investment in the field, aligning its technological advancements with regulations sensitive to public concerns about genetic modification.
Market Insights
The market dynamics represent an ever-changing landscape of the CRISPR Gene Editing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the CRISPR Gene Editing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the CRISPR Gene Editing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Synthego and SeQure Dx Partner to Provide Comprehensive Off-Target Analysis Services for CRISPR-Based Therapeutics Developers
Synthego and SeQure Dx formed a strategic alliance to advance the development of CRISPR therapeutics. This collaboration equips developers with an all-encompassing off-target editing analytic service, leveraging SeQure Dx's distinguished ONE-seq assay technology and Synthego's robust suite of synthetic guide RNAs. The seamless integration of these offerings promises to streamline the therapeutic development cycle, enhancing safety and efficiency while satisfying stringent regulatory standards. [Published On: 2024-01-23]
CRISPR QC Raises USD 10 Million in Series A Financing Round
CRISPR QC, a startup based in San Diego, concluded a Series A funding round with a significant USD 10 million investment. Specializing in assessing CRISPR/Cas9 gene-editing endeavors, CRISPR QC is pioneering the field with its innovative platform that utilizes the CRISPR-Chip, a high-precision biosensor designed to evaluate CRISPR activity accurately. This funding triumph comes from a seed funding round that garnered USD 1.6 million, reflecting growing confidence and interest in CRISPR QC's potential to transform gene editing quality control. [Published On: 2024-01-05]
Newcomer Tome Acquires Replace TX in USD 250 Million Gene Editing Deal
Tome Biosciences announced the acquisition of Replace Therapeutics in a strategic move, accelerating its footprint in the burgeoning gene editing sector. This acquisition underscores Tome's ambition to broaden its disease treatment portfolio and embodies the growing valuation of the gene editing market. Replace's contribution to Tome's suite with its ligase-mediated programmable genomic integration (L-PGI) complements Tome's existing large DNA edits, enhancing the company's capabilities in addressing various genetic conditions with high efficiency and specificity. [Published On: 2024-01-03]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the CRISPR Gene Editing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the CRISPR Gene Editing Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., AstraZeneca PLC, Beam Therapeutics Inc., Bio-Rad Laboratories, Inc., Caribou Biosciences, Inc., Cellectis S.A., CRISPR Therapeutics AG, Danaher Corporation, Editas Medicine, Inc., F. Hoffmann-La Roche AG, GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group Ltd. by Revvity, Inc., Inscripta, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Mammoth Biosciences, Inc., Merck KGaA, New England Biolabs, Inc., OriGene Technologies, Inc., Prime Medicine, Inc., Qiagen NV, Sherlock Biosciences, Inc., Thermo Fisher Scientific Inc., and ToolGen, Inc..
Market Segmentation & Coverage